FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (pedsODAC) Meeting
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, Maryland
June 20, 2018

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Lauren Tesh, PharmD, BCPS
Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Alberto S. Pappo, MD
(Chairperson, pedsODAC)
Member and Head, Division of Solid Malignancies
St Jude Children’s Research Hospital
Professor of Pediatrics
University of Tennessee Health Science Center
Memphis, Tennessee

Courtney J. Preusse, MA
(Consumer Representative)
Senior Research Administrator and CLIA Operations Director
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)

Phuong Khanh (P.K.) Morrow, MD, FACP
(Industry Representative)
Executive Medical Director, Amgen Oncology
Therapeutic Area Head, US Medical Organization
One Amgen Center Drive
Thousand Oaks, California

TEMPORARY MEMBERS (Voting)

Steven G. DuBois, MD
Director, Experimental Therapeutics
Dana-Farber/Boston Children’s Hospital
Associate Professor of Pediatrics
Harvard Medical School
Boston, Massachusetts

Ira Dunkel, MD
Attending, Pediatric Neuro-oncology
Memorial Sloan Kettering Cancer Center
New York, New York
TEMPORARY MEMBERS (Voting) (cont.)

Julia Glade Bender, MD  
Associate Professor of Pediatrics at Columbia University Medical Center  
Associate Director, Division of Pediatric Hematology, Oncology and Stem Cell Transplantation  
Medical Director, Developmental Therapeutics and Precision Medicine Programs  
New York, New York

Katherine A. Janeway, MD, MMSc  
Associate Professor of Pediatrics  
Harvard Medical School  
Senior Physician and Director Solid Tumor Service, Pediatric Oncology  
Dana-Farber Cancer Institute / Boston Children's Hospital  
Boston, Massachusetts

E. Anders Kolb, MD  
Director, Nemours Center for Cancer and Blood Disorders  
Alfred I duPont Hospital for Children  
Wilmington, Delaware

Theodore W. Laetsch, MD  
Director, Experimental Therapeutics Program  
Children’s Health  
Assistant Professor of Pediatrics, Division of Hematology-Oncology  
University of Texas Southwestern Medical Center  
Dallas, Texas

Donna M. Ludwinski  
(Patient Representative)  
Research Program Advisor  
Solving Kids’ Cancer  
New York, New York

Tobey J. MacDonald, MD  
Professor of Pediatrics  
Emory University School of Medicine  
Director, Pediatric Neuro-Oncology Program  
Aflac Cancer & Blood Disorders Center  
Children’s Healthcare of Atlanta  
Atlanta, Georgia

Rajen Mody, MD, MS  
Ruth Heyn Professor of Pediatric Oncology and Communicable Diseases  
Interim Division Director, Pediatric Hematology/Oncology/BMT  
Director, Pediatric Phase-I and Experimental Therapeutics Program  
Ann Arbor, Michigan

Kathleen A. Neville, MD, MS, MBA, FAAP, FCCP  
Professor of Pediatrics  
University of Arkansas for Medical Sciences  
Chief, Section of Clinical Pharmacology and Toxicology  
Director, Experimental Therapeutics Program  
Co-Director, Pediatric Precision Medicine Program  
Little Rock, Arkansas

Elizabeth A. Raetz, MD  
Professor of Pediatrics, NYU School of Medicine  
Director, Division of Pediatric Hematology/Oncology  
Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders  
New York, New York

Nita Seibel, MD  
Head, Pediatric Solid Tumor Therapeutics Clinical Investigations Branch, Cancer Therapy Evaluation Program/Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI) National Institutes of Health (NIH)  
Bethesda, Maryland
TEMPORARY MEMBERS (Voting) (cont.)

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malcom A. Smith IV, MD, PhD</td>
<td>Associate Branch Chief for Pediatrics, Clinical Investigations Branch, Cancer Therapy Evaluation Program/Division of Cancer Treatment and Diagnosis, NCI, NIH</td>
<td>Bethesda, Maryland</td>
</tr>
<tr>
<td>Brenda J. Weigel, MD, MSc</td>
<td>Professor</td>
<td>Division Director, Pediatric Hematology/Oncology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of Minnesota</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Developmental Therapeutics Chair</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Children’s Oncology Group</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Minneapolis, Minnesota</td>
</tr>
</tbody>
</table>

SPEAKER (Non-Voting)

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lia Gore, MD</td>
<td>(Participation in Topic 2)</td>
<td>Professor of Pediatrics, Medical Oncology, and Hematology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chief, Pediatric Hematology/Oncology/Bone Marrow Transplant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Robert J. and Kathleen A. Clark Endowed Chair in Pediatric Cancer Therapeutics and the Ergen Chair in Pediatric Oncology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Children’s Hospital Colorado</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Center for Cancer and Blood Disorders</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aurora, Colorado</td>
</tr>
</tbody>
</table>

FDA PARTICIPANTS (Non-Voting)

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Reaman, MD</td>
<td>Associate Director Oncology Sciences</td>
<td>Office of Hematology and Oncology Products (OHOP)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Office of New Drugs (OND), CDER, FDA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Associate Director for Pediatric Oncology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oncology Center of Excellence, FDA</td>
</tr>
<tr>
<td>Amy Barone, MD</td>
<td>Medical Officer</td>
<td>Division of Oncology Products 2 (DOP2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OHOP, OND, CDER, FDA</td>
</tr>
<tr>
<td>Diana Bradford, MD</td>
<td>Medical Officer</td>
<td>DOP2, OHOP, OND, CDER, FDA</td>
</tr>
<tr>
<td>Sandra J. Casak, MD</td>
<td>Senior Staff Fellow</td>
<td>DOP2, OHOP, OND, CDER, FDA</td>
</tr>
<tr>
<td>Sandra J. Casak, MD</td>
<td>Senior Staff Fellow</td>
<td>DOP2, OHOP, OND, CDER, FDA</td>
</tr>
</tbody>
</table>